Published in Transl Oncol on April 01, 2010
Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer (2010) 2.95
The autophagic tumor stroma model of cancer: Role of oxidative stress and ketone production in fueling tumor cell metabolism. Cell Cycle (2010) 2.26
Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer (2012) 1.92
MiR-210--micromanager of the hypoxia pathway. Trends Mol Med (2010) 1.90
MicroRNA-155 promotes resolution of hypoxia-inducible factor 1alpha activity during prolonged hypoxia. Mol Cell Biol (2011) 1.81
Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One (2011) 1.78
MicroRNAs as potential biomarkers in human solid tumors. Cancer Lett (2012) 1.73
miR-210: the master hypoxamir. Microcirculation (2012) 1.56
Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer (2011) 1.53
Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer (2011) 1.53
Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res (2012) 1.50
Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer (2013) 1.48
Long noncoding intronic RNAs are differentially expressed in primary and metastatic pancreatic cancer. Mol Cancer (2011) 1.42
Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer (2013) 1.39
The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochim Biophys Acta (2012) 1.26
Circulating microRNA profiling identifies a subset of metastatic prostate cancer patients with evidence of cancer-associated hypoxia. PLoS One (2013) 1.23
miR-210 is a target of hypoxia-inducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer (2013) 1.21
Micro-RNAs as diagnostic or prognostic markers in human epithelial malignancies. BMC Cancer (2011) 1.20
Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. PLoS One (2013) 1.20
Microenvironmental regulation of cancer metastasis by miRNAs. Trends Cell Biol (2013) 1.20
Hypoxia induced aggressiveness of prostate cancer cells is linked with deregulated expression of VEGF, IL-6 and miRNAs that are attenuated by CDF. PLoS One (2012) 1.18
Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer. J Cancer (2014) 1.09
Regulatory Effects of microRNA-92 (miR-92) on VHL Gene Expression and the Hypoxic Activation of miR-210 in Clear Cell Renal Cell Carcinoma. J Cancer (2011) 1.09
Advances in biomarker research for pancreatic cancer. Curr Pharm Des (2012) 1.05
MicroRNAs: Meta-controllers of gene expression in synaptic activity emerge as genetic and diagnostic markers of human disease. Pharmacol Ther (2011) 1.03
Stability of miRNA in human urine supports its biomarker potential. Biomark Med (2013) 1.02
Circulating RNAs as new biomarkers for detecting pancreatic cancer. World J Gastroenterol (2015) 1.01
Epigenetic silencing of miR-210 increases the proliferation of gastric epithelium during chronic Helicobacter pylori infection. Nat Commun (2014) 1.01
MicroRNA-196a and -196b as Potential Biomarkers for the Early Detection of Familial Pancreatic Cancer. Transl Oncol (2014) 1.00
Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. Adv Drug Deliv Rev (2014) 1.00
MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer. World J Gastroenterol (2014) 0.98
Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer. Int J Oncol (2014) 0.98
MicroRNAs in pancreatic cancer metabolism. Nat Rev Gastroenterol Hepatol (2012) 0.97
Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma. Br J Cancer (2015) 0.97
Circulating microRNAs as biomarkers for early detection of diffuse-type gastric cancer using a mouse model. Br J Cancer (2013) 0.96
MicroRNAs in prostate cancer. Prostate Int (2012) 0.96
miR-210: fine-tuning the hypoxic response. Adv Exp Med Biol (2014) 0.95
MicroRNAs in Cancer Biology and Therapy: Current Status and Perspectives. Genes Dis (2014) 0.94
Circulating microRNAs as biomarkers of acute stroke. Int J Mol Sci (2014) 0.92
HypoxamiRs and cancer: from biology to targeted therapy. Antioxid Redox Signal (2013) 0.92
MicroRNAs: promising new antiangiogenic targets in cancer. Biomed Res Int (2014) 0.91
Aberrant MicroRNAs in Pancreatic Cancer: Researches and Clinical Implications. Gastroenterol Res Pract (2014) 0.91
Roles and mechanisms of microRNAs in pancreatic cancer. World J Surg (2011) 0.90
The mix of two worlds: non-coding RNAs and hormones. Nucleic Acid Ther (2012) 0.90
MicroRNAs and long non-coding RNAs: prospects in diagnostics and therapy of cancer. Radiol Oncol (2013) 0.90
Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer. Biomed Res Int (2014) 0.90
The Role of miRNAs as Key Regulators in the Neoplastic Microenvironment. Mol Biol Int (2011) 0.90
Differential expression of plasma miR-146a in sepsis patients compared with non-sepsis-SIRS patients. Exp Ther Med (2013) 0.90
Improved blood tests for cancer screening: general or specific? BMC Cancer (2011) 0.88
Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev (2016) 0.87
MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions. World J Gastrointest Oncol (2016) 0.87
Effect of microRNA-210 on prognosis and response to chemotherapeutic drugs in pediatric acute lymphoblastic leukemia. Cancer Sci (2014) 0.87
New Concepts in Cancer Biomarkers: Circulating miRNAs in Liquid Biopsies. Int J Mol Sci (2016) 0.86
Genome-wide analysis of microRNA and mRNA expression signatures in cancer. Acta Pharmacol Sin (2015) 0.86
Circulating MicroRNA as Biomarkers: An Update in Prostate Cancer. Mol Cell Pharmacol (2011) 0.86
Noninvasive micromarkers. Clin Chem (2014) 0.86
Noncoding RNAs as potential biomarkers to predict the outcome in pancreatic cancer. Drug Des Devel Ther (2015) 0.85
MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma. PLoS One (2015) 0.85
The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluids. J Cell Mol Med (2015) 0.85
Epigenetic biomarkers in skin cancer. Cancer Lett (2012) 0.84
An Argonaute 2 switch regulates circulating miR-210 to coordinate hypoxic adaptation across cells. Biochim Biophys Acta (2014) 0.83
OxymiRs in cutaneous development, wound repair and regeneration. Semin Cell Dev Biol (2012) 0.83
Serum miRNA signature in Moyamoya disease. PLoS One (2014) 0.83
Intracellular and Extracellular miRNAs in Regulation of Angiogenesis Signaling. Curr Angiogenes (2012) 0.82
Reduction of Plasma MicroRNA-21 is Associated with Chemotherapeutic Response in Patients with Non-small Cell Lung Cancer. Chin J Cancer Res (2011) 0.82
MicroRNAs in Pancreatic Cancer: Involvement in Carcinogenesis and Potential Use for Diagnosis and Prognosis. Gastroenterol Res Pract (2015) 0.82
Overexpression of miR-210 is Associated with Poor Prognosis of Acute Myeloid Leukemia. Med Sci Monit (2015) 0.82
The molecular targets for the diagnosis and treatment of pancreatic cancer. Gut Liver (2010) 0.82
A microRNA profile associated with Opisthorchis viverrini-induced cholangiocarcinoma in tissue and plasma. BMC Cancer (2015) 0.81
Circulating miR-106a is a Novel Prognostic and Lymph Node Metastasis Indicator for Cholangiocarcinoma. Sci Rep (2015) 0.81
Plasma microRNA profiles: identification of miR-744 as a novel diagnostic and prognostic biomarker in pancreatic cancer. Br J Cancer (2015) 0.81
Analysis of microRNA niches: techniques to measure extracellular microRNA and intracellular microRNA in situ. Methods Mol Biol (2013) 0.81
Methylated DNA and microRNA in body fluids as biomarkers for cancer detection. Int J Mol Sci (2013) 0.81
Targeting CSCs in tumor microenvironment: the potential role of ROS-associated miRNAs in tumor aggressiveness. Curr Stem Cell Res Ther (2014) 0.81
Liquid biopsy in patients with pancreatic cancer: Circulating tumor cells and cell-free nucleic acids. World J Gastroenterol (2016) 0.80
The Role of microRNAs in the Diagnosis and Treatment of Pancreatic Adenocarcinoma. J Clin Med (2016) 0.80
Use of miRNAs as biomarkers in sepsis. Anal Cell Pathol (Amst) (2015) 0.80
Essential role of miRNAs in orchestrating the biology of the tumor microenvironment. Mol Cancer (2016) 0.80
Pancreatic cancer biomarkers and their implication in cancer diagnosis and epidemiology. Cancers (Basel) (2010) 0.79
Identifying cancer specific functionally relevant miRNAs from gene expression and miRNA-to-gene networks using regularized regression. PLoS One (2013) 0.78
Customized Internal Reference Controls for Improved Assessment of Circulating MicroRNAs in Disease. PLoS One (2015) 0.78
MicroRNA-100 and microRNA-21 as markers of survival and chemotherapy response in pancreatic ductal adenocarcinoma UICC stage II. Clin Epigenetics (2015) 0.77
Suffocating cancer: hypoxia-associated epimutations as targets for cancer therapy. Clin Epigenetics (2011) 0.77
Circulating microRNAs and Bioinformatics Tools to Discover Novel Diagnostic Biomarkers of Pediatric Diseases. Genes (Basel) (2017) 0.77
Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. Oncotarget (2016) 0.76
miRNAs As Diagnostic and Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma and Its Precursor Lesions: A Review. Biomark Insights (2015) 0.76
Oridonin alters the expression profiles of microRNAs in BxPC-3 human pancreatic cancer cells. BMC Complement Altern Med (2015) 0.75
Blood microRNAs as potential diagnostic markers for hemorrhagic stroke. Neural Regen Res (2017) 0.75
Role of non-coding RNAs in pancreatic cancer: the bane of the microworld. World J Gastroenterol (2014) 0.75
Circulating DNA and Micro-RNA in Patients with Pancreatic Cancer. Pancreat Disord Ther (2015) 0.75
Visualization of exosome-mediated miR-210 transfer from hypoxic tumor cells. Oncotarget (2016) 0.75
Circulating microRNAs in breast cancer: novel diagnostic and prognostic biomarkers. Cell Death Dis (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res (2008) 20.59
A microRNA signature of hypoxia. Mol Cell Biol (2006) 7.24
hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res (2008) 4.84
miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther (2007) 3.93
Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell (2009) 3.68
MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila) (2009) 3.55
Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys (2000) 3.22
MicroRNA: implications for cancer. Virchows Arch (2007) 3.17
MicroRNA regulation of DNA repair gene expression in hypoxic stress. Cancer Res (2009) 2.93
Hypoxia response and microRNAs: no longer two separate worlds. J Cell Mol Med (2008) 1.93
Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine. Clin Cancer Res (2004) 1.68
MicroRNAs and cancer. APMIS (2007) 1.66
Diagnosis and management of skin resurfacing-related complications. Oral Maxillofac Surg Clin North Am (2009) 0.89
Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 13.52
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 12.98
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Lysyl oxidase is essential for hypoxia-induced metastasis. Nature (2006) 8.28
Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med (2008) 6.82
Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell (2009) 6.66
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol (2010) 4.39
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol (2008) 4.10
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell (2009) 3.68
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. Nat Immunol (2004) 3.25
XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res (2004) 3.24
Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer (2009) 2.77
Changes in choroidal thickness after panretinal photocoagulation in patients with type 2 diabetes. Retina (2015) 2.71
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J Clin Oncol (2007) 2.51
Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood (2010) 2.48
Mesenchymal stem cells: a new strategy for immunosuppression and tissue repair. Cell Res (2010) 2.46
First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study. J Clin Oncol (2012) 2.36
The genome and transcriptomes of the anti-tumor agent Clostridium novyi-NT. Nat Biotechnol (2006) 2.31
Sample classification from protein mass spectrometry, by 'peak probability contrasts'. Bioinformatics (2004) 2.28
The relationship between human papillomavirus status and other molecular prognostic markers in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys (2009) 2.26
Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res (2005) 2.20
Short telomeres and prognosis of hypertension in a chinese population. Hypertension (2009) 2.18
Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood (2009) 2.15
Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res (2013) 2.15
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2005) 2.10
Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology (2011) 2.10
The unfolded protein response: a novel component of the hypoxic stress response in tumors. Mol Cancer Res (2005) 2.09
Structure-based design of novel inhibitors of the MDM2-p53 interaction. J Med Chem (2012) 2.01
Multiplexed protein detection by proximity ligation for cancer biomarker validation. Nat Methods (2007) 1.99
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res (2009) 1.99
TMEM16A induces MAPK and contributes directly to tumorigenesis and cancer progression. Cancer Res (2012) 1.98
Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis. Cancer Res (2006) 1.97
Identification of osteopontin as a prognostic plasma marker for head and neck squamous cell carcinomas. Clin Cancer Res (2003) 1.96
Regulatory T cell populations in sepsis and trauma. J Leukoc Biol (2007) 1.96
MiR-210--micromanager of the hypoxia pathway. Trends Mol Med (2010) 1.90
Stereotactic body radiotherapy for colorectal liver metastases: a pooled analysis. Cancer (2011) 1.87
Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2008) 1.81
Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients. Crit Care (2011) 1.78
miR-221 and miR-155 regulate human dendritic cell development, apoptosis, and IL-12 production through targeting of p27kip1, KPC1, and SOCS-1. Blood (2011) 1.73
The contribution of CD4+ CD25+ T-regulatory-cells to immune suppression in sepsis. Shock (2007) 1.71
An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res (2006) 1.71
Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2009) 1.71
Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys (2007) 1.69
Non-small cell lung cancer clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 1.68
Results of a phase 2 study examining the effects of omitting elective neck irradiation to nodal levels IV and Vb in patients with N(0-1) nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2012) 1.68
The role of tumor cell-derived connective tissue growth factor (CTGF/CCN2) in pancreatic tumor growth. Cancer Res (2009) 1.64
A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science (2006) 1.64
18Fluorodeoxyglucose PET is prognostic of progression-free and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys (2010) 1.61
MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol (2011) 1.61
Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys (2010) 1.60
GM130, a cis-Golgi protein, regulates meiotic spindle assembly and asymmetric division in mouse oocyte. Cell Cycle (2011) 1.60
Single-fraction stereotactic body radiation therapy and sequential gemcitabine for the treatment of locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys (2011) 1.57
Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer. Clin Chem (2008) 1.57
High-dose single-fraction radiotherapy: exploiting a new biology? Int J Radiat Oncol Biol Phys (2008) 1.57
Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer (2014) 1.55
Comparison of treatment results between adult and juvenile nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys (2009) 1.54
Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol (2006) 1.53
Genetic control of developmental changes induced by disruption of Arabidopsis histone deacetylase 1 (AtHD1) expression. Genetics (2003) 1.52
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab (2005) 1.51
Identification of mitogen-activated protein kinase signaling pathways that confer resistance to endoplasmic reticulum stress in Saccharomyces cerevisiae. Mol Cancer Res (2005) 1.48
Expression of the c-Met oncogene by tumor cells predicts a favorable outcome in classical Hodgkin's lymphoma. Haematologica (2011) 1.46
Adrenal myelolipoma associated with hyperandrogenemia. Int J Urol (2012) 1.46
Syndecan-1 and E-cadherin expression in differentiated type of early gastric cancer. World J Gastroenterol (2005) 1.45
Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol (2005) 1.45
The regulatory role of AT 1 receptor on activated HSCs in hepatic fibrogenesis:effects of RAS inhibitors on hepatic fibrosis induced by CCl(4). World J Gastroenterol (2000) 1.43
4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Hum Gene Ther (2010) 1.40
Dopamine transporter and D2 receptor binding densities in mice prone or resistant to chronic high fat diet-induced obesity. Behav Brain Res (2006) 1.40
BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol (2012) 1.40
Interconversion of ATP binding and conformational free energies by tryptophanyl-tRNA synthetase: structures of ATP bound to open and closed, pre-transition-state conformations. J Mol Biol (2003) 1.39
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol (2008) 1.38
[Some misunderstandings of deqi phenomenon: from historic review to experimental study]. Zhongguo Zhen Jiu (2008) 1.38
Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure. Clin Cancer Res (2009) 1.38
Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer (2011) 1.37
PET of EGFR antibody distribution in head and neck squamous cell carcinoma models. J Nucl Med (2009) 1.36
Expression and prognostic significance of a panel of tissue hypoxia markers in head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys (2007) 1.36
Imaging the unfolded protein response in primary tumors reveals microenvironments with metabolic variations that predict tumor growth. Cancer Res (2009) 1.34
Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res (2008) 1.34
Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. Ann Thorac Surg (2003) 1.34
Clinical cancer advances 2010: annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol (2010) 1.33
A dosimetric model of duodenal toxicity after stereotactic body radiotherapy for pancreatic cancer. Int J Radiat Oncol Biol Phys (2010) 1.33
Identification of Arabidopsis rat mutants. Plant Physiol (2003) 1.32
Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CCl(4). World J Gastroenterol (2000) 1.30
Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res (2010) 1.29
Retrospective IMRT dose reconstruction based on cone-beam CT and MLC log-file. Int J Radiat Oncol Biol Phys (2008) 1.29
Hepatocyte growth factor promotes cancer cell migration and angiogenic factors expression: a prognostic marker of human esophageal squamous cell carcinomas. Clin Cancer Res (2005) 1.29
Comparison of the effects of traditional box-moxibustion and eletrothermal Bian-stone moxibustion on volume of blood flow in the skin. J Tradit Chin Med (2011) 1.28